These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38432600)

  • 21. Improvement of Oral Absorption of Poorly Water-Soluble Drugs by Solid Dispersions with Amphiphilic Phospholipid Polymer.
    Yoshie K; Ishihara K
    J Pharm Sci; 2022 Nov; 111(11):3141-3148. PubMed ID: 36028136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation and Characterization of Aprepitant Solid Dispersion with HPMCAS-LF.
    Liu J; Li Y; Ao W; Xiao Y; Bai M; Li S
    ACS Omega; 2022 Nov; 7(44):39907-39912. PubMed ID: 36385804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and Evaluation of Probucol-Phospholipid Complex with Enhanced Bioavailability and No Food Effect.
    Qian Y; Chen G; Wang J; Ren L
    AAPS PharmSciTech; 2018 Nov; 19(8):3599-3608. PubMed ID: 30238303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of HPMCAS/curcumin amorphous solid dispersion in enhancing dissolution and chemical stability of curcumin].
    Liang Q; Wang YR; Deng YY
    Zhongguo Zhong Yao Za Zhi; 2019 Aug; 44(15):3305-3311. PubMed ID: 31602887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vilazodone-phospholipid mixed micelles for enhancing oral bioavailability and reducing pharmacokinetic variability between fed and fasted states.
    El Said HS; Lalatsa A; Al-Mahallawi AM; Saddar El Leithy E; Ghorab DM
    Int J Pharm; 2022 Sep; 625():122080. PubMed ID: 35932929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomimetic Dissolution: A Tool to Predict Amorphous Solid Dispersion Performance.
    Puppolo MM; Hughey JR; Dillon T; Storey D; Jansen-Varnum S
    AAPS PharmSciTech; 2017 Nov; 18(8):2841-2853. PubMed ID: 28560506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Combined Utilization of Plasdone-S630 and HPMCAS-HF in Ziprasidone Hydrochloride Solid Dispersion by Hot-Melt Extrusion to Enhance the Oral Bioavailability and No Food Effect.
    Xue X; Chen G; Xu X; Wang J; Wang J; Ren L
    AAPS PharmSciTech; 2019 Jan; 20(1):37. PubMed ID: 30604142
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Jermain SV; Lowinger MB; Ellenberger DJ; Miller DA; Su Y; Williams RO
    Mol Pharm; 2020 Aug; 17(8):2789-2808. PubMed ID: 32520562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solution behavior of PVP-VA and HPMC-AS-based amorphous solid dispersions and their bioavailability implications.
    Qian F; Wang J; Hartley R; Tao J; Haddadin R; Mathias N; Hussain M
    Pharm Res; 2012 Oct; 29(10):2765-76. PubMed ID: 22315020
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of phospholipid digests and bile acid pool variations on the crystallization of atazanavir from supersaturated solutions.
    Enright EF; Joyce SA; Gahan CGM; Taylor LS
    Eur J Pharm Biopharm; 2020 Aug; 153():68-83. PubMed ID: 32473291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extensive improvement of oral bioavailability of mebendazole, a brick dust, by polymer-containing SNEDDS preparation: Disruption of high crystallinity by utilizing its counter ion.
    Sumimoto Y; Okawa S; Inoue T; Masuda K; Maruyama M; Higaki K
    Eur J Pharm Biopharm; 2022 Mar; 172():213-227. PubMed ID: 35134511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of in vitro dissolution conditions for the in vivo predictability of an amorphous solid dispersion containing a pH-sensitive carrier.
    Wendelboe J; Knopp MM; Khan F; Chourak N; Rades T; Holm R
    Int J Pharm; 2017 Oct; 531(1):324-331. PubMed ID: 28827200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biopredictive capability assessment of two dissolution/permeation assays, µFLUX™ and PermeaLoop™, using supersaturating formulations of Posaconazole.
    Holzem FL; Weck A; Schaffland JP; Stillhart C; Klein S; Bauer-Brandl A; Brandl M
    Eur J Pharm Sci; 2022 Sep; 176():106260. PubMed ID: 35842141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability and Bioavailability Enhancement of Telmisartan Ternary Solid Dispersions: the Synergistic Effect of Polymers and Drug-Polymer(s) Interactions.
    Shi X; Xu T; Huang W; Fan B; Sheng X
    AAPS PharmSciTech; 2019 Mar; 20(4):143. PubMed ID: 30887265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of food effect on in vitro drug dissolution into biorelevant media: Contributions of solubility enhancement and relatively low colloid diffusivity.
    Jamil R; Polli JE
    Eur J Pharm Sci; 2022 Oct; 177():106274. PubMed ID: 35944878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New supersaturating drug delivery system as strategy to improve apparent solubility of candesartan cilexetil in biorelevant medium.
    Pinto JMO; Leão AF; Alves GF; Mendes C; França MT; Fernandes D; Stulzer HK
    Pharm Dev Technol; 2020 Jan; 25(1):89-99. PubMed ID: 31583925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymeric Precipitation Inhibitor Assisted Supersaturable SMEDDS of Efavirenz Based on Experimental Observations and Molecular Mechanics.
    Singh M; Singh D; Mahajan S; Sheikh BA; Bedi N
    Curr Drug Deliv; 2021; 18(4):513-530. PubMed ID: 32735521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How to Improve Solubility and Dissolution of Irbesartan by Fabricating Ternary Solid Dispersions: Optimization and In-Vitro Characterization.
    Akram A; Irfan M; Abualsunun WA; Bukhary DM; Alissa M
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states.
    Litou C; Patel N; Turner DB; Kostewicz E; Kuentz M; Box KJ; Dressman J
    Eur J Pharm Sci; 2019 Oct; 138():105031. PubMed ID: 31386891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.